Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Colorectal Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Non-Resectable Hepatocellular Carcinoma;   Recurrent Cholangiocarcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Intestinal Carcinoma;   Small Intestinal Adenocarcinoma;   Stage III Colorectal Cancer;   Stage III Gastric Cancer;   Stage III Hepatocellular Carcinoma;   Stage III Pancreatic Cancer;   Stage III Small Intestinal Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Small Intestinal Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Small Intestinal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Colorectal Cancer;   Stage IV Gastric Cancer;   Stage IV Hepatocellular Carcinoma;   Stage IV Pancreatic Cancer;   Stage IV Small Intestinal Cancer;   Stage IVA Colorectal Cancer;   Stage IVA Hepatocellular Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Hepatocellular Carcinoma;   Stage IVB Pancreatic Cancer;   Unresectable Pancreatic Carcinoma;   Unresectable Small Intestinal Carcinoma
Interventions:   Drug: XL888;   Biological: Pembrolizumab
Sponsors:   Emory University;   Merck Sharp & Dohme Corp.;   Exelixis
Not yet recruiting - verified March 2017

http://ift.tt/2olgmED